Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigation in the Pathogenesis of Liver Disease in Patients with Inborn Errors of Bile Acid Metabolism
2011-004259-38Phase 3
- Sponsor
- Asklepion Pharmaceuticals
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cholic acid in congenital bile acid synthesis disorder (CBASD) and inborn error of bile acid metabolism (IEBAM), sponsored by Asklepion Pharmaceuticals. Primary endpoint: Urinary bile acid profile at 12 months.
02
Drugs
cholic acid
03
Conditions
congenital bile acid synthesis disorder (CBASD)inborn error of bile acid metabolism (IEBAM)
Beyond the preview
Go deeper on 2011-004259-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004259-38.